Get the Stockscreener App
2.60
1.70%
-0.045
Dogwood Therapeutics Inc stock is traded at $2.60, with a volume of 43,493.
It is down -1.70% in the last 24 hours and down -47.90% over the past month.
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$2.645
Open:
$2.73
24h Volume:
43,493
Relative Volume:
0.71
Market Cap:
$3.52M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.00%
1M Performance:
-47.90%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.58
$2.87
1-Week Range:
$2.09
$2.87
52-Week Range:
$1.62
$5.29
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
2.60 | 3.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase - Marketscreener.com
Dogwood Therapeutics Faces Potential Asset Loss and Financial Risks Amid Sealbond Repurchase Option - MSN
Dogwood Therapeutics faces potential Nasdaq delisting - Investing.com
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study - The Manila Times
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 - GlobeNewswire
Zacks Small Cap Has Negative Outlook of DWTX FY2024 Earnings - Defense World
Barclays Forecasts Strong Price Appreciation for Arista Networks (NYSE:ANET) Stock - Defense World
Dogwood Therapeutics Announces Third Quarter Financial ResultsOn November 7, 2024, Dogwood Therapeutics, Inc. (Nasdaq: DWTX) disclosed its financial performance for the third quarter ending September 30, 2024. The company, newly formed in Octob - Defense World
DWTX: Phase 2 Long COVID Results Expected Soon - Smartkarma
U.S. Stock market top losers:1847 Holdings LLC drop by 41.56%, Interactive Strength Inc. declined by 27.76% during mid day trading - Business Upturn
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
White Cliff Minerals Director Increases Shareholding - MSN
Dogwood Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results - GlobeNewswire
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia - Marketscreener.com
Craig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - MSN
Peregrine Gold Ltd Confirms Prospectus Lodgement for Security Issue - MSN
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Marketscreener.com
Flutter Entertainment Files Block Listing Application for Ordinary Shares - Defense World
Nano Nuclear Energy Inc. Completes Full Exercise of Over-Allotment Option, Generating Approximately $37.7 Million in Net Proceeds - Defense World
AgEagle Aerial Systems Appoints Kevin Lowdermilk as Independent Director - Defense World
Dogwood Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
DWTXDogwood Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia - Marketscreener.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
Dogwood Therapeutics : Corporate Presentation (Virios DWTX Inc. Corporate Overview Q4 2024) - Marketscreener.com
Healthpeak Properties raised to Buy at Deutsche on leasing prospects - MSN
Dogwood Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($1.40) Per Share (NASDAQ:DWTX) - Defense World
Dogwood Therapeutics, Inc.DWTX: Virios Therapeutics Becomes Dogwood Therapeutics - Smartkarma
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
Financial Metrics Check: Dogwood Therapeutics Inc. (DWTX)’s Ratios for Trailing Twelve Months - The Dwinnex
VIRIOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Dogwood Therapeutics (DWTX) Stock Chart and Price History 2024 - MarketBeat
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 - Marketscreener.com
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - Marketscreener.com
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com
United States shares higher at close of trade; Dow Jones Industrial Average up 1.03% - Investing.com India
Virios Therapeutics shares target raised on Wex merger news - Investing.com
New obesity treatment has this tiny co soaring 💃 - RagingBull
Virios Therapeutics Transforms into Dogwood Therapeutics - Yahoo Finance
CKLIFE SCIENCES Hopes to Introduce Investors for Newly Merged Dogwood (DWTX.US) - AASTOCKS.com
Unit Of Li Ka-Shing’s CK Life Sciences To Merge With Nasdaq-Listed Biotech Company In $100 Million Deal - Forbes
Virios Therapeutics announces strategic merger and financing - Investing.com
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. to Combine to Form Dogwood Therapeutics, Inc. - Orrick
Virios Therapeutics And Wex Pharmaceuticals To Merge - citybiz
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders - Marketscreener.com
Virios Therapeutics, Wex Pharmaceuticals announce business combination agreement - TipRanks
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
There is no financial data for Dogwood Therapeutics Inc (DWTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):